Delivery Order 36F79720D0099-36C26221F0077
Award Date 11/18/20
Potential Completion Date 11/23/21
Potential Value $103K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92161, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order to Otsuka America Pharmaceutical Inc. for Jynarque (tolvaptan) on September 26, 2023, with a ceiling value of $12,224.60. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2023, was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and did not utilize a set-aside designation. The product will be delivered to...
- The Department of Veterans Affairs, Veterans Integrated Service Network 22, awarded a delivery order to Otsuka America Pharmaceutical Inc. for Tolvaptan 15mg (Jynarque) on December 20, 2022, with a ceiling value of $94,669.12. This firm-fixed price delivery order, which was completed by December 19, 2023, was issued without a set-aside designation and performed in Pittsburgh, Pennsylvania. Jynarque is a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and...
- The Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order to Otsuka America Pharmaceutical Inc. on June 4, 2024, for the supply of Tolvaptan (Jynarque) 45mg/15mg tablets (NDC: 59148-0087-28) with a ceiling value of $12,580.72. This firm fixed-price delivery order, which is set to be completed by July 4, 2024, is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and does not utilize any small business set-aside...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order valued at $37,742.16 to Otsuka America Pharmaceutical Inc. on June 25, 2024, with an ultimate completion date of August 26, 2024. This firm-fixed price delivery order procures Jynarque (tolvaptan), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. The award was issued under the Pharmaceuticals and Drugs...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 6 (VISN 6), awarded a delivery order to Otsuka America Pharmaceutical Inc. on March 21, 2022, for the supply of Jynarque (tolvaptan), a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia. This firm fixed-price delivery order carries a ceiling value of $11,413.72 and is scheduled for completion by April 1, 2022, with performance occurring in Pittsburgh, Pennsylvania....
- On July 1, 2023, the Department of Veterans Affairs (VA), specifically Veterans Integrated Service Network 22, awarded a delivery order to Otsuka America Pharmaceutical Inc. for Jynarque (tolvaptan) with a ceiling value of $284,695.42. This firm fixed-price delivery order, with an ultimate completion date of June 30, 2024, was issued without set-aside designation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract supports the VA's provision of specialty...
- Otsuka America Pharmaceutical Inc. was awarded a delivery order by Veterans Integrated Service Network 5 (VISN 5) for Jynarque 90mg/30mg on November 12, 2021, with a ceiling value of $10,375.04. The contract is firm fixed price with no set-aside designation and was completed by November 17, 2021. This delivery order was issued under the company's broader Blanket Purchase Agreement for Jynarque valued at $83.3 million with the VA's National Acquisition Center, which operates under the...
- Otsuka America Pharmaceutical Inc. received a firm fixed-price delivery order valued at approximately $297K from the Department of Veterans Affairs Veterans Integrated Service Network 22 (VISN 22) for Tolvaptan (Jynarque), a specialty pharmaceutical medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, awarded on April 8, 2022, with a completion date of September 30, 2022, was issued without a set-aside designation and is being performed in...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order to Otsuka America Pharmaceutical Inc. on April 7, 2023, for the supply of Jynarque (tolvaptan) 90mg/30mg pharmaceutical products. This firm-fixed-price delivery order, valued at $12,195.72, represents a task order issued under the parent Blanket Purchase Agreement on the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract does not utilize a set-aside designation and carries...
- On November 3, 2020, the Department of Veterans Affairs' Veterans Integrated Service Network 6 (VISN 6) awarded a delivery order to Otsuka America Pharmaceutical Inc. for the supply of Jynarque (tolvaptan), a specialty pharmaceutical medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, valued at $10,099.21, was awarded on a firm-fixed price basis with no set-aside designation and is scheduled for completion by November 6, 2020. Performance will...